#AACR20: Io­vance rev­els in promis­ing lung can­cer da­ta out of Mof­fitt as TIL ther­a­py trig­gers 2 com­plete re­spons­es

Shrink­ing, or even erad­i­cat­ing, sol­id tu­mors has been a Holy Grail for cell ther­a­pies, whose ef­fects so far have been lim­it­ed to blood can­cers. At the Amer­i­can As­so­ci­a­tion for Can­cer Re­search, re­searchers from Mof­fitt Can­cer Cen­ter are pre­sent­ing ear­ly da­ta sug­gest­ing that tu­mor-in­fil­trat­ing lym­pho­cytes can do the trick for non-small cell lung can­cer.

It’s a small num­ber: two com­plete re­spons­es out of 13 pa­tients who re­ceived per­son­al­ized TIL ther­a­py. But con­sid­er­ing that these pa­tients had pro­gressed fol­low­ing treat­ment with Op­di­vo — a stan­dard-of-care check­point in­hibitor — and that the tu­mor has stayed away for al­most a year, the re­sults count as promis­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER